Peroxisome proliferator-activated receptor-β as a target for wound healing drugs

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 1, 2004, Pages 39-48

  Tan, Nguan Soon ^a   Michalik, Liliane ^a   Desvergne, Béatrice ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Apoptosis; Inflammation; Keratinocytes; Macrophages; Nuclear receptor; Wound repair

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; ARACHIDONIC ACID; CLOFIBRIC ACID; CYCLOOXYGENASE 2; CYTOKINE; GELATINASE B; GLUCOCORTICOID; GROWTH FACTOR; HYDROCORTISONE; I KAPPA B BETA; ICOSANOID; INTERLEUKIN 1BETA; LIGAND; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTAGLANDIN A1; PROSTAGLANDIN D2; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOUND HEALING PROMOTING AGENT; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ACUTE DISEASE; APOPTOSIS; BIOSYNTHESIS; CELL COMMUNICATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; EPITHELIZATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KERATINOCYTE; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN INJURY; SURVIVAL; TISSUE REPAIR; WOUND HEALING;

EID: 1242352525     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.1.39     Document Type: Review

References (69)

1. COULOMBE PA: Wound epithelialization: accelerating the pace of discovery. J. Invest. Dermatol. (2003) 121(2):219-230.
2. WERNER S, GROSE R: Regulation of wound healing by growth factors and cytokines. Physiol. Rev. (2003) 83(3):835-870.
3. GROSE R, WERNER S: Wound healing studies in transgenic and knockout mice. A review. Methods Mol. Med. (2003) 78:191-216.
4. ROBERTS AB, SPORN MB: Transforming Growth Factor-β. In: Transforming Growth Factor-β. The Molecular and Cellular Biology of Wound Repair. Clark RAF (Ed.), Plenum Press, New York (1996):275-308.
5. MARTIN P: Wound healing - aiming for perfect skin regeneration. Science (1997) 276(5309):75-81.
6. ANGEL P, SZABOWSKI A: Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. Biochem. Pharmacol. (2002) 64(5-6):949-956.
7. ANGEL P, SZABOWSKI A, SCHORPP-KISTNER M: Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene (2001) 20(19):2413-2423.
8. TAN NS, MICHALIK L, NOY N et al.: Critical roles of PPAR β/δ in keratinocyte response to inflammation. Genes Dev. (2001) 15(24):3263-3277.
9. KERSTEN S, DESVERGNE B, WAHLI W: Roles of PPARs in health and disease. Nature (2000) 405(6785):421-424.
10. LEE CH, OLSON P, EVANS RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology (2003) 144(6):2201-2207.
11. DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. (1999) 20(5):649-688.
12. YU S, RAO S, REDDY JK: Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. (2003) 3(6):561-572.
13. KERSTEN S, MANDARD S, ESCHER P et al.: The peroxisome proliferator-activated receptor α regulates amino acid metabolism. FASEB J. (2001) 15(11):1971-1978.
14. KERSTEN S, SEYDOUX J, PETERS JM, GONZALEZ FJ, DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. (1999) 103(11):1489-1498.
15. LEONE TC, WEINHEIMER CJ, KELLY DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA (1999) 96(13 ):7473-7478.
16. DELERIVE P, FRUCHART JC, STAELS B: Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. (2001) 169(3):453-459.
17. 4 pathway to inflammation control. Nature (1996) 384(6604):39-43.
18. ROSEN ED, WALKEY CJ, PUIGSERVER P, SPIEGELMAN BM: Transcriptional regulation of adipogenesis. Genes Dev. (2000) 14(11):1293-1307.
19. ARNER P: The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. (2003) 14(3):137-145.
20. FRANCIS GA, FAYARD E, PICARD F, AUWERX J: Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. (2003) 65:261-311.
21. BECKMAN J, RAJI A, PLUTZKY J: Peroxisome proliferator-activated receptor γ and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr. Opin. Cardiol. (2003) 18:479-485.
22. BRAISSANT O, FOUFELLE F, SCOTTO C, DAUCA M, WAHLI W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology (1996) 137(1):354-366.
23. ESCHER P, BRAISSANT O, BASU-MODAK S, MICHALIK L, WAHLI W, DESVERGNE B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology (2001) 142(10):4195-4202.
24. SALUJA I, GRANNEMAN JG, SKOFF RP: PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia (2001) 33(3):191-204.
25. PETERS JM, LEE SS, LI W et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. (2000) 20(14):5119-5128.
26. OLIVER WR Jr, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98(9 ):5306-5311.
27. VOSPER H, PATEL L, GRAHAM TL et al.: The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J. Biol. Chem. (2001) 276(47):44258-44265.
28. DRESSEL U, ALLEN TL, PIPPAL JB, ROHDE PR, LAU P, MUSCAT GE: The peroxisome proliferator activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling to skeletal muscle cells. Mol. Endocrinol. (2003) 17(12):2477-2493.
29. LUQUET S, LOPEZ-SORIANO J, HOLST D et al.: Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J. (2003) 17(15):2299-2301.
30. HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 99(3):335-345.
31. BARAK Y, LIAO D, HE W et al.: Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA (2002) 99(1):303-308.
32. MICHALIK L, DESVERGNE B, TAN NS et al.: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol. (2001) 154(4):799-814.
33. LEE CH, CHAWLA A, URBIZTONDO N, LIAO D, BOISVERT WA, EVANS RM: Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science (2003) 302(5644):453-457.
34. BINDER CJ, CHANG MK, SHAW PX et al.: Innate and acquired immunity in atherogenesis. Nat. Med. (2002) 8(11):1218-1226.
35. STEINBERG D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8(11):1211-1217.
36. DENT AL, VASANWALA FH, TONEY LM: Regulation of gene expression by the proto-oncogene BCL-6. Crit. Rev. Oncol. Hematol. (2002) 41(1):1-9.
37. TONEY LM, CATTORETTI G, GRAF JA et al.: BCL-6 regulates chemokine gene transcription in macrophages. Nat. Immunol. (2000) 1(3):214-220.
38. SCHMUTH M, HAQQ CM, CAIRNS WJ et al.: Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. (2003). In Press.
39. HANLEY K, JIANG Y, HE SS et al.: Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARα. J. Invest. Dermatol. (1998) 110(4):368-375.
40. KOMUVES LG, HANLEY K, LEFEBVRE AM et al.: Stimulation of PPARα promotes epidermal keratinocyte differentiation in vivo. J. Invest. Dermatol. (2000) 115(3):353-360.
41. KOMUVES LG, HANLEY K, MAN MQ, ELIAS PM, WILLIAMS ML, FEINGOLD KR: Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARα activators restores tissue homeostasis. J. Invest. Dermatol. (2000) 115(3):361-367.
42. WONG P, COULOMBE PA: Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. J. Cell Biol. (2003) 163(2):327-337.
43. INADA R, MATSUKI M, YAMADA K et al.: Facilitated wound healing by activation of the transglutaminase I gene. Am. J. Pathol. (2000) 157(6):1875-1882.
44. MATSUKI M, YAMASHITA F, ISHIDA-YAMAMOTO A et al.: Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase I (keratinocyte transglutaminase). Proc. Natl. Acad. Sci. USA (1998) 95(3):1044-1049.
45. DI POÏ N, TAN NS, MICHALIK L, WAHLI W, DESVERGNE B: Antiapoptotic role of PPARΒ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell (2002) 10(4):721-733.
46. FRANKE TF, CANTLEY LC: Apoptosis. A Bad kinase makes good. Nature (1997) 390(6656):116-117.
47. FRANKE TF, KAPLAN DR, CANTLEY LC: PI3K: downstream AKTion blocks apoptosis. Cell (1997) 88(4):435-437.
48. FLYNN P, WONGDAGGER M, ZAVAR M, DEAN NM, STOKOE D: Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr. Biol. (2000) 10(22):1439-1442.
49. NICHOLSON KM, ANDERSON NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. (2002) 14(5):381-395.
50. ASHCROFT GS, YANG X, GLICK AB et al.: Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. (1999) 1(5):260-266.
51. MARTIN P, D'SOUZA D, MARTIN J er al.: Wound healing in the PU.1 null mouse - tissue repair is not dependent on inflammatory cells. Curr. Biol. (2003) 13(13):1122-1128.
52. LEVADE T, AUGE N, VELDMAN RJ, CUVILLIER O, NEGRE-SALVAYRE A, SALVAYRE R: Sphingolipid mediators in cardiovascular cell biology and pathology. Circ. Res. (2001) 89(11):957-968.
53. GAUR U, AGGARWAL BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. (2003) 66(8):1403-1408.
54. MASSAGUE J: How cells read TGF-β signals. Nat. Rev. Mol. Cell. Biol. (2000) 1(3):169-178.
55. FORMAN BM, CHEN J, EVANS RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA (1997) 94(9):4312-4317.
56. WESTERGAARD M, HENNINGSEN J, JOHANSEN C et al.: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor κb in normal and lesional psoriatic skin. J. Invest. Dermatol. (2003) 121(5):1104-1117.
57. LIM H, GUPTA RA, MA WG et al.: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev. (1999) 13(12):1561-1574.
58. LIM H, DEY SK: A novel pathway of prostacyclin signaling - hanging out with nuclear receptors. Endocrinology (2002) 143(9):3207-3210.
59. GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N. Engl. J. Med. (1995) 332(9):581-588.
60. ELLIS CN, VARANI J, FISHER GJ et al.: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-γ inhibit keratinocyte proliferation. Arch. Dermatol. (2000) 136(5):609-616.
61. MAZZALUPO S, WAWERSIK MJ, COULOMBE PA: An ex vivo assay to assess the potential of skin keratinocytes for wound epithelialization. J. Invest. Dermatol. (2002) 118(5):866-870.
62. MAAS-SZABOWSKI N, SZABOWSKI A, STARK HJ et al.: Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J. Invest. Dermatol. (2001) 116(5):816-820.
63. INDRA AK, LI M, BROCARD J et al.: Targeted somatic mutagenesis in mouse epidermis. Horm. Res. (2000) 54(5-6):296-300.
64. LI M, INDRA AK, WAROT X et al.: Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis. Nature (2000) 407(6804):633-636.
65. JAECKEL EC, RAJA S, TAN J et al.: Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. (2001) 127(10):1253-1259.
66. TONG BJ, TAN J, TAJEDA L et al.: Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ in human endometrial adenocarcinoma. Neoplasia (2000) 2(6):483-490.
67. GUPTA RA, TAN J, KRAUSE WF et al.: Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl. Acad. Sci. USA (2000) 97(24):13275-13280.
68. SEGAWA Y, YOSHIMURA R, HASE T et al.: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate (2002) 51(2):108-116.
69. MICHALIK L, DESVERGNE B, WAHLI W: Peroxisome proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer (2004) 4(1):61-70.